| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| May 1, 2026 | ±1.7% | -0.2% | over-priced |
| November 4, 2025 | ±1.9% | -0.0% | over-priced |
| August 5, 2025 | ±2.1% | -1.0% | over-priced |
| May 1, 2025 | ±2.3% | +0.9% | over-priced |
| October 30, 2024 | ±1.6% | +0.7% | over-priced |
| August 2, 2024 | ±2.3% | -4.2% | under-priced |
| May 1, 2024 | ±1.3% | +0.1% | over-priced |
| November 1, 2023 | ±2.0% | -0.1% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2026 | $5.94 | $49.8B | $16.5B |
| Q4 FY2025 | $4.64 | $45.8B | $13.0B |
| Q3 FY2025 | $5.07 | $46.4B | $14.4B |
| Q2 FY2025 | $5.24 | $44.9B | $15.0B |
JPMorgan Chase & Co. (JPM) reports in 94 days, with the next report estimated for September 15, 2026. Across the last 8 reports, options priced an average ±1.9% earnings move while the stock actually moved 0.9% on average — the market has systematically over-priced JPM's earnings risk. Fundamentals into the print: EPS up 17.2% year-over-year, revenue up 10.0%. QuantLogix's live 5-factor engine currently reads JPM as a buy at 59/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →